000153 丰原药业
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入3,261,4231.16%4,275,4374,004,0203,652,2173,321,182
减:营业总成本3,112,6881.90%4,098,5763,849,1773,527,3933,234,933
    其中:营业成本2,525,8666.28%3,176,2892,873,7492,565,7402,169,965
               财务费用21,5184.67%25,78629,90438,39840,679
               资产减值损失(1,279)-65.71%(8,336)(11,089)(14,109)(7,822)
公允价值变动收益(9,916)-31.00%(6,921)11,0809,399(1,070)
投资收益9,90389.64%5,3423,74233118,601
    其中:对联营企业和合营企业的投资收益----15(1)----
营业利润183,198-3.03%213,254202,098156,677130,555
利润总额185,883-2.17%214,893202,292159,834138,112
减:所得税费用40,792-16.19%57,59651,35241,97936,016
净利润145,0912.66%157,297150,941117,855102,097
减:非控股权益(2,212)95.15%(1,989)(3,486)(5,128)(1,624)
股东净利润147,3033.40%159,286154,427122,984103,720

市场价值指针
每股收益 (元) *0.3173.39%0.4800.4870.3940.332
每股派息 (元) *----0.1500.1000.100--
每股净资产 (元) *4.296-23.51%5.6915.2054.8964.528
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容